One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Enanta Pharmaceuticals Inc before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Enanta Pharmaceuticals Inc’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Enanta Pharmaceuticals Inc’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Enanta Pharmaceuticals Inc (ENTA)

Before we jump into Enanta Pharmaceuticals Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Enanta Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in the discovery and development of small molecule drugs, with an emphasis on treatments for viral infections. Its primary wholly owned research and development programs are in virology, namely respiratory syncytial virus (RSV), SARS-CoV-2, Hepatitis B virus (HBV) and Human metapneumovirus (hMPV). The Company has discovered glecaprevir, the second of two protease inhibitors discovered and developed for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is a co-formulated direct-acting antiviral (DAA), combination treatment for HCV, which is marketed under the tradenames MAVYRET and MAVIRET. Its lead clinical candidate for the treatment of chronic infection with HBV, is EDP-514. Its lead clinical candidate for COVID-19 is EDP-235. The Company's clinical stage program for RSV, with two compounds in clinical trials includes EDP-938 and EDP-323.

Want to learn more about Enanta Pharmaceuticals Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Enanta Pharmaceuticals Inc. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Enanta Pharmaceuticals Inc’s Stock Price as of Market Close

As of February 08, 2023, 9:30 AM CST, Enanta Pharmaceuticals Inc’s stock price was $61.17.

Enanta Pharmaceuticals Inc is up 12.05% from its previous closing price of $54.59.

During the last market session, Enanta Pharmaceuticals Inc’s stock traded between $51.85 and $54.87. Currently, there are 20.76 million shares of Enanta Pharmaceuticals Inc stock available for purchase.

Unfortunately, Enanta Pharmaceuticals Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Enanta Pharmaceuticals Inc Stock Price History

Enanta Pharmaceuticals Inc’s (ENTA) price is currently up 14.59% so far this month.

During the month of February, Enanta Pharmaceuticals Inc’s stock price has reached a high of $62.06 and a low of $50.14.

Over the last year, Enanta Pharmaceuticals Inc has hit prices as high as $79.50 and as low as $37.59. Year to date, Enanta Pharmaceuticals Inc’s stock is down 18.2%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Enanta Pharmaceuticals Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of February 07, 2023, there were 0 analysts who downgraded Enanta Pharmaceuticals Inc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Enanta Pharmaceuticals Inc’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Enanta Pharmaceuticals Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Enanta Pharmaceuticals Inc (ENTA) by visiting AAII Stock Evaluator.

Relative Price Strength of Enanta Pharmaceuticals Inc

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of February 07, 2023, Enanta Pharmaceuticals Inc has a weighted four-quarter relative price strength of 4.62%, which translates to a Momentum Score of 70 and is considered to be Strong.

Want to learn more about how Enanta Pharmaceuticals Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Enanta Pharmaceuticals Inc Stock Price: Bottom Line

As of February 8, 2023, Enanta Pharmaceuticals Inc’s stock price is $61.17, which is up 12.05% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Enanta Pharmaceuticals Inc’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.